Covered recipient · General Payments record
RONALD S STUMBRIS
Allopathic & Osteopathic Physicians General Practice
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$33.77
1 record · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $33.77 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Mindray DS USA, Inc. | $33.77 | 1 |
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD S STUMBRIS
NPI 1891858346 · CMS profile ID 900986
Allopathic & Osteopathic Physicians / General Practice
PALOS HEIGHTS, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1891858346?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD S STUMBRIS, NPI 1891858346, CMS profile ID 900986. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891858346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). RONALD S STUMBRIS, NPI 1891858346, CMS profile ID 900986. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891858346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- RONALD S STUMBRIS, NPI 1891858346, CMS profile ID 900986, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1891858346?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
1 matching record · $33.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–1 of 1.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Mindray DS USA, Inc. | $33.77 | 03/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1057352201 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2021, 2023
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2021 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,369,938.26 | 29 |
| PY2024 | Recipient | $1,309.00 | 1 |
| PY2024 | Principal investigator | $541,430.78 | 15 |
| PY2023 | Principal investigator | $1,109,001.73 | 11 |
| PY2022 | Principal investigator | $581,681.06 | 31 |
| PY2021 | Recipient | $248.98 | 1 |
| PY2021 | Principal investigator | $135,534.19 | 24 |
| PY2020 | Principal investigator | $15,893.58 | 3 |
| PY2019 | Principal investigator | $5,000.00 | 1 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
25 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $2,343.29 | 12/31/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK | A Phase2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia | No dispute reported | 06/30/2026 | 848740407 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,545.30 | 12/22/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806259001 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $1,858.50 | 12/20/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851032039 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,320.80 | 12/16/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258995 |
| Principal investigator 1 | ACADIA Pharmaceuticals Inc | $10,000.00 | 11/26/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | ACP-044-005 | No dispute reported | 06/30/2026 | 837698135 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,807.80 | 11/24/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806259005 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,744.30 | 11/11/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258993 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $4,410.00 | 11/03/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258985 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $12,483.00 | 10/27/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851029279 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,348.30 | 10/21/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258999 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,404.00 | 10/07/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258989 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $11,722.50 | 09/28/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851027817 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,404.00 | 09/22/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258943 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $6,030.00 | 08/30/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851026999 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 08/05/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258935 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,000.00 | 08/05/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia | No dispute reported | 06/30/2026 | 806258939 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $16,654.50 | 07/27/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851026581 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $15,439.50 | 06/29/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851025437 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $350.00 | 06/08/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma | No dispute reported | 06/30/2026 | 806259103 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $6,088.50 | 06/01/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851024955 |
| Principal investigator 1 | Eli Lilly and Company | $198.64 | 04/30/2021 | Covered Recipient Teaching Hospital MONTEFIORE MEDICAL CENTER | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | No dispute reported | 06/30/2026 | 819449275 |
| Principal investigator 1 | Biohaven Pharmaceuticals, Inc. | $6,000.00 | 03/29/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine | No dispute reported | 06/30/2026 | 851023477 |
| Principal investigator 1 | Eli Lilly and Company | $3,605.07 | 03/29/2021 | Non-covered Recipient Entity BIO BEHAVIORAL HEALTH | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | No dispute reported | 06/30/2026 | 819452177 |
| Recipient | Eli Lilly and Company | $248.98 | 03/04/2021 | Covered Recipient Physician | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | No dispute reported | 06/30/2026 | 819446301 |
| Principal investigator 1 | Eli Lilly and Company | $276.19 | 03/03/2021 | Non-covered Recipient Entity HEALTHCARE RESEARCH NETWORK II LLC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | No dispute reported | 06/30/2026 | 819459825 |